Group
ROS1 targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | ROS1 inhibitor |
| Drugs in group | Taletrectinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
ROS1 TKIs predominantly interact additively rather than synergistically with ionizing radiation, lacking the reinforcement in cellular injury that would drive a major theoretical increase in normal-tissue side effects (Jost et al. Neoplasia 2022). Despite this favorable radiobiological profile, the class's inherent adverse events—such as pneumonitis, gastrointestinal symptoms, and neurologic events—could theoretically compound with radiation-induced inflammation in overlapping treatment fields (Desilets et al. Cancer 2025; Jiang et al. Frontier Pharmacology 2025; Barbato et al. Clinical Cancer Research 2024).
The data above refer to patients treated with ROS1 targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.